Sonoma Pharmaceuticals (SNOA) Total Current Liabilities (2011 - 2026)

Sonoma Pharmaceuticals' Total Current Liabilities history runs 16 years deep, the most recent figure standing at $4.8 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 17.97% year-over-year to $4.8 million in Q1 2026; TTM through Mar 2026 was $4.8 million, a 17.97% increase from a year earlier, with the FY2026 full-year figure at $4.8 million, up 17.97% from the prior year.
• Total Current Liabilities improved to $4.8 million in Q1 2026 per SNOA's latest filing, from $4.2 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $5.8 million in Q1 2022 and bottomed at $3.1 million in Q4 2023.
• The 5-year median for Total Current Liabilities is $3.9 million (2022), against an average of $4.1 million.
• Across the five-year window, Total Current Liabilities surged 42.69% in 2022 and plunged 36.12% in 2023, its largest moves.
• Year by year, Total Current Liabilities stood at $3.9 million in 2022, then decreased by 21.86% to $3.1 million in 2023, then rose by 20.46% to $3.7 million in 2024, then advanced by 13.88% to $4.2 million in 2025, then advanced by 14.58% to $4.8 million in 2026.
• Per Business Quant, the three latest SNOA Total Current Liabilities figures stand at $4.8 million (Q1 2026), $4.2 million (Q4 2025), and $4.3 million (Q3 2025).